Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Antimicrob Agents ; 61(6): 106811, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37037319

RESUMO

INTRODUCTION: Multidrug-resistant (MDR) Gram-negative organisms cause life-threatening infections, and the incidence is rising globally. Timely therapy for these infections has a direct impact on patient survival. This study aimed to determine the impact of a multidisciplinary diagnostic and antimicrobial stewardship (AMS) workflow on time to appropriate therapy (TAP) for these infections using novel beta-lactam/beta-lactamase inhibitors. METHODS: This was a retrospective quasi-experimental study of adult patients with carbapenem-resistant Enterobacterales (CRE) and multidrug-resistant Pseudomonas (MDR PsA) infections at a 1500 bed university hospital. Included patients who received ≥ 72 hours of ceftazidime-avibactam (CZA) or ceftolozane-tazobactam (C/T) from December 2017 to December 2019. During the pre-intervention period (December 2017 to December 2018), additional susceptibilities (including CZA and C/T) were performed only upon providers' request. In 2019, reflex algorithms were implemented for faster identification and testing of all CRE/MDR PsA isolates. Results were communicated in real-time to the AMS team to tailor therapy. RESULTS: A total of 99 patients were included, with no between-group differences at baseline. The median age was 60 years and 56 (56.7%) were in intensive care at the time of culture collection. Identified organisms included 71 (71.7%) MDR PsA and 26 CRE, of which 18 were carbapenemase producers (Klebsiella-producing carbapenemase = 12, New Delhi metallo-ß-lactamase = 4, Verona integron-encoded metallo-ß-lactamase = 2). The most common infections were pneumonia (49.5%) and bacteraemia (30.3%). A decrease was found in median TAP (103 [IQR 76.0-156.0] vs. 75 [IQR 56-100] hours; P < 0.001). Median time from culture collection to final susceptibility results was shorter in the post-intervention group (123 vs. 93 hours; P < 0.001). CONCLUSION: This study identified improvement in TAP in MDR PsA and CRE infections with implementation of a reflex microbiology workflow and multidisciplinary antimicrobial stewardship initiatives.


Assuntos
Gestão de Antimicrobianos , Artrite Psoriásica , Humanos , Pessoa de Meia-Idade , Antibacterianos/uso terapêutico , Antibacterianos/farmacologia , Estudos Retrospectivos , Fluxo de Trabalho , Artrite Psoriásica/tratamento farmacológico , Ceftazidima/farmacologia , Bactérias Gram-Negativas , Inibidores de beta-Lactamases/uso terapêutico , Inibidores de beta-Lactamases/farmacologia , beta-Lactamases , Carbapenêmicos/farmacologia , Combinação de Medicamentos , Compostos Azabicíclicos/farmacologia , Testes de Sensibilidade Microbiana , Pseudomonas aeruginosa
2.
Transpl Infect Dis ; 20(1)2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29064133

RESUMO

Infections with carbapenemase-producing carbapenem-resistant Enterobacteriaceae represent an emergent problem worldwide. Treatment of infections caused by New Delhi metallo-beta-lactamase (NDM)-harboring Enterobacteriaceae is particularly challenging as it frequently involves the use of nephrotoxic agents, which is problematic in kidney transplant recipients and non-renal transplant patients with marginal kidney function. We present two cases of urinary tract infections caused by NDM-harboring Enterobacteriaceae successfully treated with a combination of "double carbapenem" and oral fosfomycin.


Assuntos
Carbapenêmicos/uso terapêutico , Infecções por Enterobacteriaceae/tratamento farmacológico , Enterobacteriaceae/efeitos dos fármacos , Fosfomicina/uso terapêutico , Transplante de Rim/efeitos adversos , Infecções Urinárias/tratamento farmacológico , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Carbapenêmicos/administração & dosagem , Enterobacteriaceae/enzimologia , Infecções por Enterobacteriaceae/etiologia , Infecções por Enterobacteriaceae/microbiologia , Fosfomicina/administração & dosagem , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Resultado do Tratamento , Infecções Urinárias/complicações , Infecções Urinárias/microbiologia , beta-Lactamases/biossíntese , beta-Lactamases/efeitos dos fármacos
3.
Antimicrob Agents Chemother ; 59(10): 5903-8, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26386029

RESUMO

New antibiotic options are urgently needed for the treatment of carbapenem-resistant Enterobacteriaceae infections. We report a 64-year-old female with prolonged hospitalization following an intestinal transplant who developed refractory bacteremia due to a serine carbapenemase-producing pandrug-resistant isolate of Klebsiella pneumoniae. After failing multiple antimicrobial regimens, the patient was successfully treated.


Assuntos
Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Proteínas de Bactérias/biossíntese , Intestino Delgado/efeitos dos fármacos , Infecções por Klebsiella/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos , beta-Lactamases/biossíntese , Antivirais/uso terapêutico , Compostos Azabicíclicos/uso terapêutico , Bacteriemia/microbiologia , Bacteriemia/patologia , Carbapenêmicos/uso terapêutico , Ceftazidima/uso terapêutico , Colectomia , Colistina/uso terapêutico , Combinação de Medicamentos , Farmacorresistência Bacteriana Múltipla , Feminino , Ganciclovir/análogos & derivados , Ganciclovir/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Intestino Delgado/microbiologia , Intestino Delgado/transplante , Infecções por Klebsiella/microbiologia , Infecções por Klebsiella/patologia , Klebsiella pneumoniae/enzimologia , Klebsiella pneumoniae/crescimento & desenvolvimento , Meropeném , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Minociclina/análogos & derivados , Minociclina/uso terapêutico , Tienamicinas/uso terapêutico , Tigeciclina , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Valganciclovir
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA